FOUND: Diagnostics | Mind Blowing Facts

Is Revvity Stock Outperforming the Dow?

Revvity has notably outperformed the Dow over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart · Sep 23

Revvity Stock: Is Wall Street Bullish or Bearish?

Revvity has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart · Aug 24

Is Co-Diagnostics National Security’s Next Diagnostic Pick?

Global health emergencies are shifting sovereign biodefense strategies toward decentralized diagnostic networks capable of deploying rapid stockpiles.

MarketBeat · May 28

Co-Diagnostics Stock Is Rocketing Higher Monday: What's Going On?

Co-Diagnostics, Inc. (NASDAQ:CODX) shares are trading higher Monday after the company signed a definitive agreement with Arabian Eagle to establish CoMira Diagnostics and localize its Co-Dx PCR platform across the Middle East.

Benzinga · Oct 27, 2025

Revvity Lifts Profit Outlook, Launches $1 Billion Buyback Plan

Revvity, Inc. (NYSE:RVTY) announced its third-quarter 2025 financial results on Monday. The company’s performance was mixed compared to analyst expectations, and the stock declined immediately.

Benzinga · Oct 27, 2025

EXCLUSIVE: Co-Diagnostics Inks JV With Saudi Arabia Firm For Middle East Market

Co-Diagnostics, Inc. (NASDAQ:CODX) announced on Monday that it has entered into a joint venture agreement with the Kingdom of Saudi Arabia (KSA) based Arabian Eagle Manufacturing.

Benzinga · Oct 27, 2025

Quest Diagnostics Reports Q3 Earnings, Shares Slide

Shares of Quest Diagnostics (NASDAQ:DGX) are falling Tuesday after the medical laboratories company shared mixed earnings results.

Benzinga · Oct 21, 2025

Co-Diagnostics Stock Plunges 28% In Pre-Market Despite Strategic Saudi Partnership

Co-Diagnostics Inc. (NASDAQ:CODX) shares dropped 28.26% to $0.46 in pre-market trading on Tuesday, wiping out the gains from Monday’s 80.76% surge, which had closed at $0.64, according to Benzinga Pro data.

Benzinga · Sep 17, 2025

This Quest Diagnostics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga · Aug 25, 2025

Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity

Quest Diagnostics Inc (NYSE:DGX) may be encountering what you might call a post-earnings digestion dance. Initially, DGX stock jumped higher, perhaps due to the algorithms and retail traders responding in unison to the better-than-expected results for the second quarter. But the next day, the security slipped, possibly as fund managers…

Benzinga · Jul 24, 2025